Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180 | 1.00 | CDC25B (0.39) | CDC25B | |
| Methyl Alcohol SCHEMBL18284553 | 0.94 | CDC25B (0.36) | CDC25B | |
| SCHEMBL4574418 | 0.90 | CDC25B (0.38) | CDC25B | |
| SCHEMBL7737681 | 0.87 | CDC25B (0.41) | CDC25B | |
| Pyrazole SCHEMBL7031994 | 0.82 | — | — | |
| SCHEMBL2975734 | 0.77 | CDC25B (0.48) | CDC25B | |
| SCHEMBL30276371 | 0.73 | CDC25B (0.31) | CDC25B | |
| SCHEMBL4588164 | 0.73 | CDC25B (0.31) | CDC25B | |
| SCHEMBL4020923 | 0.72 | CDC25B (0.36) | CDC25B | |
| SCHEMBL18155064 | 0.71 | CYP1A2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562828-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3562828-C0 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4313988-A4 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-14 | — | — | US | disclosed |
| EP-3892623-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-10 | — | — | EP | disclosed |
| US-20240208982-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. | 2024-06-27 | — | — | US | disclosed |
| EP-4313988-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313988-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3529250-B1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023109761-A1 | CRYSTAL OF PYRAZOLOPYRIMIDINONE COMPOUND AND SALT THEREOF | 贝达药业股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | CDC25B 4513/4885 |
| US-20240208982-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | CYP2C19, CYP3A4, CYP2C9 | CDC25B 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.